Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma

Oncology

Volumn 71, Issue 1-2, 2007, Pages 49-53

  Micha, John P ^a   Goldstein, Bram H ^a,d   Graham, Cheri ^a   Rettenmaier, Mark A ^a   Brown III, John V ^a   Hu, Jim C ^b   Markman, Maurie ^c  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Gynecologic Oncology Associates   (United States)

Author keywords

Consolidation therapy; Gynecologic oncology; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE;

EID: 34247148946     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100987     Document Type: Article

References (16)

1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. du Bois A, Luck HJ, Meier W. Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
4. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group study. Ann Oncol 1997;8:327-333.
5. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-289.
6. Bertelsen K, Jakobsen A, Stroyer J Nielsen K, Sandberg E, Andersen JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group (DACOVA) trial. Gynecol Oncol 1993;49:30-36.
7. Gershenson DM, Mitchell M, Atkinson N, Silva EG, Kavanagh JJ, Morris M, Burke TW, Warner D, Wharton JT: The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: 'maintenance' therapy reconsidered. Gynecol Oncol 1992;47:7-13.
8. Rothenberg ML, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82:317-322.
9. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465. 10 Markman M, Liu P, Wilczynski S, Monk B, Copeland L, Alberts D: Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG 9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/ PAC. Proc Am Soc Clin Oncol 2006;24:18S.
10. Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV: Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 2004;94:719-724.
11. Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M: Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005;96:132-135.
12. Vergote I, Rustin GJS, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MKB, Friedlander M, Jakobsen A, Vermorken JB: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000;92:1534-1535.
13. Disilvestro PA, Fisher M, Pearl ML, Buhl A, Chalas E, Valea FA: Pilot phase 2 trial of 4 months of maintenance pegylated liposomal doxorubicin in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. Gynecol Obstet Invest 2007;63:1-6.
14. Dearnley DD, McMeekin DS: Consolidation therapy in ovarian cancer: where do we stand? Curr Opin Obstet Gynecol 2006;18:3-7.
15. Lee SJ, Lee JW, Min JA, Park CS, Kim BG, Lee JH, Bae DS. A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. Int J Gynecol Cancer 2006;16:95-100.
16. Skinner EN, Boruta DM, Gehrig PA, Boggess JF, Fowler WC, Van Le L: Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended followup. Gynecol Oncol 2005;98:59-62.